Emrosi is a drug owned by Journey Medical Corp. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 07, 2039. Details of Emrosi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11364212 | Methods for treating inflammatory skin conditions |
Jan, 2039
(13 years from now) | Active |
| US11191740 | Methods for treating inflammatory skin conditions |
Jan, 2039
(13 years from now) | Active |
| US10905664 | Methods for treating inflammatory skin conditions |
Jan, 2039
(13 years from now) | Active |
FDA has granted several exclusivities to Emrosi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Emrosi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Emrosi.
Exclusivity Information
Emrosi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Emrosi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2027 |
US patents provide insights into the exclusivity only within the United States, but Emrosi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Emrosi's family patents as well as insights into ongoing legal events on those patents.
Emrosi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Emrosi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 07, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Emrosi Generic API suppliers:
Minocycline Hydrochloride is the generic name for the brand Emrosi. 25 different companies have already filed for the generic of Emrosi, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Emrosi's generic
Alternative Brands for Emrosi
There are several other brand drugs using the same active ingredient (Minocycline Hydrochloride) as Emrosi. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Bausch |
| |||
| Epi Hlth |
| |||
| Journey |
| |||
| Orapharma |
| |||
| Rempex |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Minocycline Hydrochloride, Emrosi's active ingredient. Check the complete list of approved generic manufacturers for Emrosi
About Emrosi
Emrosi is a drug owned by Journey Medical Corp. Emrosi uses Minocycline Hydrochloride as an active ingredient. Emrosi was launched by Journey in 2024.
Approval Date:
Emrosi was approved by FDA for market use on 01 November, 2024.
Active Ingredient:
Emrosi uses Minocycline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Minocycline Hydrochloride ingredient
Dosage:
Emrosi is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |